Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists Stendörren in connection with EQT Real Estate II’s cash offer to the shareholders in Stendörren
Mandate

Vinge assists Stendörren in connection with EQT Real Estate II’s cash offer to the shareholders in Stendörren

December 05, 2018 Capital Markets and Public M&A

Vinge has assisted Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with EQT Real Estate II’s, through Chicago Holding AB (“Chicago Holding”), cash offer to the shareholders in Stendörren.

Chicago Holding offers SEK 100.25 in cash for every A- and B-share in Stendörren. The offer value amounts to approximately SEK 2 823 million based on a total of 28,155,641 outstanding shares in Stendörren. 
 
Vinge’s team has primarily consisted of Jesper Schönbeck, David Andersson, Joel Wahlberg, Boris Kotur, Milad Kamali and Viktoria Owetz. 
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026